

REFERENCES

1. Powles T; ESMO Guidelines Committee. ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol.* 2024; S0923-7534(24)00676-8.
2. Dreno, B., Khosrotehrani, K., De Barros Silva, G. et al. The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus. *Support Care Cancer* , 2023; 31, 672.
3. Adler NR, Aung AK, Ergen EN, Trubiano J, Goh MS, Phillips EJ. "Recent advances in the understanding of severe cutaneous adverse reactions". *The British Journal of Dermatology.* 2017; 177 (5): 1234–1247.
4. Haanen, J. et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology.* 2022; Volume 33, Issue 12, 1217 - 1238
5. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), V5; 2017.
6. Bryan J. Schneider et al., Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. *JCO*,2021; 39, 4073-4126.
7. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol.* 2018; 36(17):1714-68.
8. Leucht K, Ali N, Foller S, Grimm MO. Management of Immune-Related Adverse Events from Immune-Checkpoint Inhibitors in Advanced or Metastatic Renal Cell Carcinoma. *Cancers (Basel).* 2022; 14(18):4369
9. Williams, L.A., et Al. ONS Guidelines™ for cancer treatment–related skin toxicity. *Oncology Nursing Forum.* 2020; 47(5), 539–556
10. Schonfeld SJ, Tucker MA, Engels EA, et al. Immune-Related Adverse Events After Immune Checkpoint Inhibitors for Melanoma Among Older Adults. *JAMA Netw Open.* 2022; 5(3):e223461.
11. Pneumocystis pneumonia, Treatments Summary; British National Formulary (BNF)-NICE. 2025; Available at: <https://bnf.nice.org.uk/treatment-summaries/pneumocystis-pneumonia/> [Accessed May 2025]
12. Tull TJ, Benton E. Immunobullous disease. *Clin Med (Lond).* 2021; 21(3):162-165.
13. Merli M, et al., Autoimmune bullous dermatoses in cancer patients treated by immunotherapy: a literature review and Italian multicentric experience. *Front Med (Lausanne).* 2023; 20;10:1208418.
14. Wiley K, Ebanks GL Jr, Shelton G, Strelo J, Ciccolini K. Skin Toxicity: Clinical Summary of the ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity. *Clin J Oncol Nurs.* 2020;24(5):561-565.
15. Cancer Network. Renal Cell Carcinoma: Overlapping Toxicity in TKI/IO Combination Therapy. Available at: <https://www.cancernetwork.com/view/renal-cell-carcinoma-overlapping-toxicity-in-tki-io-combination-therapy> [Accessed May 2025].
16. Lacouture, M.E. et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. *Annals of Oncology*, Volume 32, Issue 2, 157 – 170
17. Jideani, A. I. O., Silungwe, H., Takalani, T., Omolola, A. O., Udeh, H. O., & Anyasi, T. A. Antioxidant-rich natural fruit and vegetable products and human health. *International Journal of Food Properties*, 2021, 24(1), 41–67.
18. Church DD, Hirsch KR, Park S, Kim IY, Gwin JA, Pasiakos SM, Wolfe RR, Ferrando AA. Essential Amino Acids and Protein Synthesis: Insights into Maximizing the Muscle and Whole-Body Response to Feeding. *Nutrients.* 2020 Dec 2;12(12):3717.
19. 12 foods scientifically proven to boost skin health. Available at <https://www.medicalnewstoday.com/articles/322986>
20. Cartee TV, Alam M, Armbrrecht ES, Behera A, Lawrence N, Bordeaux JS, Baum CL, Rossi A, Maher IA. Patient-Centered Outcomes for Skin Cancer Management: Utilization of a Patient Delphi Process to Identify Important Treatment Themes. *Dermatol Surg.* 2019 Feb;45(2):246-253.
21. National Cancer Institute. Communication in Cancer Care (PDQ®)—Patient Version. Available at: <https://www.cancer.gov/about-cancer/coping/adjusting-to-cancer/communication-pdq> [Accessed October 2024].